MGX
Metagenomi Therapeutics, Inc.
$1.29
-0.03 (-2.27%)
At close · Jul 8
Market Cap
$47.44M
Shares
37,646,858
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.29
Open$1.31
Day$1.28–1.35
52W$1.13–3.95
Avg vol 30d170K
Short int1.8M · 4.7% float · 11.4d
Short vol36%
Last earningsNov 12, 2025
DataFeb 2024–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−1%
below
RSI (14)
54
neutral
MACD trend
Positive
52-week position
6%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−25%
trailing
YTD return
−20%
this year
Relative strength
−32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +5 funds added
Insider flow
Distributing
Net -$9.3K over 90 days · 100% sells
Short interest
Falling
4.66% of float · ▼ -4.1% MoM · 11.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 2-yr low, contrarian setup
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
−52%
Y/Y
EPS growth
0%
Y/Y
Free cash flow
$-89.5M
Balance sheet
$41.7M
net cash
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +5 funds added
Insider flow
Distributing
Net -$9.3K over 90 days · 100% sells
Short interest
Falling
4.66% of float · ▼ -4.1% MoM · 11.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $1 · 6%
52-wk high $4
vs 200-day avg -24%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MGX
this stock
Metagenomi Therapeutics, Inc.
|
$47.44M | -20.4% | +16.8% | — | 4.7% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MGX | +8.4% | +0.0% | -25.0% | +8.4% | -20.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +8.6% | -0.8% | -32.4% | +8.6% | -29.7% |